{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T22:07:48Z","timestamp":1789250868437,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"DOI":"10.1038\/s41409-026-03033-6","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T21:44:26Z","timestamp":1789249466000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["GVHD prophylaxis with PTCy, ATG, PTCy+ATG, or no in vivo T-cell depletion in RIC matched-donor PBSC transplantation for AML and MDS"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7328-0355","authenticated-orcid":false,"given":"Tereza","family":"Coman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Morisset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4045-8310","authenticated-orcid":false,"given":"Raynier","family":"Devillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5909-2742","authenticated-orcid":false,"given":"Maud","family":"D\u2019Aveni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2944-3812","authenticated-orcid":false,"given":"Frederic","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7032-5180","authenticated-orcid":false,"given":"Jacques Olivier","family":"Bay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2846-9428","authenticated-orcid":false,"given":"Jean","family":"El-Cheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Bilger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude-Eric","family":"Bulabois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7728-5804","authenticated-orcid":false,"given":"Cristina","family":"Castilla-Llorente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0812-2937","authenticated-orcid":false,"given":"Patrice","family":"Ceballos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Chalandon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Chantepie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magalie","family":"Joris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3142-5581","authenticated-orcid":false,"given":"Patrice","family":"Chevallier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Alani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jer\u00f4me","family":"Cornillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Daguindeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8873-2868","authenticated-orcid":false,"given":"Edouard","family":"Forcade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chama","family":"Mokeddem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaelle","family":"Guillerm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0543-9592","authenticated-orcid":false,"given":"H\u00e9l\u00e8ne","family":"Labussiere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Lewalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4460-5939","authenticated-orcid":false,"given":"Mikael","family":"Loschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Maertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Malard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Val\u00e8re","family":"Malfuson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natacha","family":"Maillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Baptiste","family":"Mear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Nguyen-Quoc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Pivert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1897-0227","authenticated-orcid":false,"given":"Xavier","family":"Poire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3732-5442","authenticated-orcid":false,"given":"Marie-Th\u00e9r\u00e8se","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Suarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Turlure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alban","family":"Villate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4524-8782","authenticated-orcid":false,"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Raus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1388-9876","authenticated-orcid":false,"given":"Marie","family":"Robin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7338-1081","authenticated-orcid":false,"given":"Mauricette","family":"Michallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,12]]},"reference":[{"key":"3033_CR1","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1038\/s41375-024-02225-7","volume":"38","author":"O Penack","year":"2024","unstructured":"Penack O, Abouqateb M, Peczynski C, Boreland W, Kr\u00f6ger N, Stelljes M, et al. ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?. Leukemia. 2024;38:1156\u201363.","journal-title":"Leukemia"},{"key":"3033_CR2","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1182\/bloodadvances.2016002766","volume":"1","author":"YL Kasamon","year":"2017","unstructured":"Kasamon YL, Ambinder RF, Fuchs EJ, Zahurak M, Rosner GL, Bola\u00f1os-Meade J, et al. Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide. Blood Adv. 2017;1:288\u201392.","journal-title":"Blood Adv"},{"key":"3033_CR3","first-page":"208.e1","volume":"29","author":"BE Shaw","year":"2023","unstructured":"Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, et al. Three-year outcomes in recipients of mismatched unrelated bone marrow donor transplants using post-transplantation cyclophosphamide: follow-up from a national marrow donor program-sponsored prospective clinical trial. Transpl Cell Ther. 2023;29:208.e1\u2013208.e6.","journal-title":"Transpl Cell Ther"},{"key":"3033_CR4","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1016\/S2352-3026(19)30220-0","volume":"7","author":"I Walker","year":"2020","unstructured":"Walker I, Panzarella T, Couban S, Couture F, Devins G, Elemary M, et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2020;7:e100\u2013e111.","journal-title":"Lancet Haematol"},{"key":"3033_CR5","doi-asserted-by":"publisher","first-page":"40.e1","DOI":"10.1016\/j.jtct.2022.09.010","volume":"29","author":"LJ Arcuri","year":"2023","unstructured":"Arcuri LJ, Kerbauy MN, Kerbauy LN, de Santos FPS, Ribeiro AAF, Hamerschlak N. ATG in HLA-matched, peripheral blood, hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome: a secondary analysis of a CIBMTR database. Transplant Cell Ther. 2023;29:40.e1\u201340.e4.","journal-title":"Transplant Cell Ther"},{"key":"3033_CR6","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/bmt.2013.204","volume":"49","author":"F Baron","year":"2014","unstructured":"Baron F, Labopin M, Blaise D, Lopez-Corral L, Vigouroux S, Craddock C, et al. Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2014;49:389\u201396.","journal-title":"Bone Marrow Transplant"},{"key":"3033_CR7","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/s41409-025-02692-1","volume":"60","author":"A Piekarska","year":"2025","unstructured":"Piekarska A, Abouqateb M, Boreland W, Peczynski C, Zaucha JM, Kr\u00f6ger N, et al. Improved GVHD-free relapse-free survival when rATG\/ATLG is used in allo-HCT from matched sibling donors\u2013an EBMT registry study by the Transplant Complications Working Party. Bone Marrow Transplant. 2025;60:1574\u201383.","journal-title":"Bone Marrow Transplant"},{"key":"3033_CR8","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41409-017-0043-y","volume":"53","author":"R Devillier","year":"2018","unstructured":"Devillier R, Labopin M, Chevallier P, Ledoux M-P, Soci\u00e9 G, Huynh A, et al. Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation. Bone Marrow Transplant. 2018;53:431\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"3033_CR9","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1200\/JCO.2017.76.0512","volume":"35","author":"M Mohty","year":"2017","unstructured":"Mohty M, Malard F. Antithymocyte globulin for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2017;35:3993\u20135.","journal-title":"J Clin Oncol"},{"key":"3033_CR10","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.1016\/S2352-3026(18)30221-7","volume":"6","author":"J Bola\u00f1os-Meade","year":"2019","unstructured":"Bola\u00f1os-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, et al. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematol. 2019;6:e132\u2013e143.","journal-title":"Lancet Haematol"},{"key":"3033_CR11","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","volume":"388","author":"J Bola\u00f1os-Meade","year":"2023","unstructured":"Bola\u00f1os-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023;388:2338\u201348.","journal-title":"N Engl J Med"},{"key":"3033_CR12","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1182\/bloodadvances.2021005847","volume":"6","author":"AEC Broers","year":"2022","unstructured":"Broers AEC, de Jong CN, Bakunina K, Hazenberg MD, van Marwijk Kooy M, de Groot MR, et al. Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial. Blood Adv. 2022;6:3378\u201385.","journal-title":"Blood Adv"},{"key":"3033_CR13","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/S2352-3026(23)00342-3","volume":"11","author":"O Penack","year":"2024","unstructured":"Penack O, Marchetti M, Aljurf M, Arat M, Bonifazi F, Duarte RF, et al. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2024;11:e147\u2013e159.","journal-title":"Lancet Haematol"},{"key":"3033_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00990-3","volume":"14","author":"E Brissot","year":"2024","unstructured":"Brissot E, Labopin M, Labussi\u00e8re H, Fossard G, Chevallier P, Guillaume T, et al. Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10\/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial. Blood Cancer J. 2024;14:31.","journal-title":"Blood Cancer J"},{"key":"3033_CR15","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/bjh.19031","volume":"203","author":"M Aydin","year":"2023","unstructured":"Aydin M, de Leeuw DC, Rutten CE, Visser OJ, Tang MW, van Roessel C, et al. ATG versus PTCy in matched unrelated donor haematopoietic stem cell transplantations with non-myeloablative conditioning. Br J Haematol. 2023;203:439\u201345.","journal-title":"Br J Haematol"},{"key":"3033_CR16","doi-asserted-by":"publisher","first-page":"4792","DOI":"10.1182\/bloodadvances.2024013468","volume":"8","author":"Y Chalandon","year":"2024","unstructured":"Chalandon Y, Eikema D-J, Moiseev I, Ciceri F, Koster L, Vydra J, et al. Unrelated donor transplantation with posttransplant cyclophosphamide vs ATG for myelodysplastic neoplasms. Blood Adv. 2024;8:4792\u2013802.","journal-title":"Blood Adv"},{"key":"3033_CR17","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1002\/cncr.35004","volume":"129","author":"S Giebel","year":"2023","unstructured":"Giebel S, Labopin M, Salmenniemi U, Soci\u00e9 G, Bondarenko S, Blaise D, et al. Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2023;129:3735\u201345.","journal-title":"Cancer"},{"key":"3033_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01032-8","volume":"14","author":"O Penack","year":"2024","unstructured":"Penack O, Abouqateb M, Peczynski C, Boreland W, G\u00fclbas Z, Gedde-Dahl T, et al. PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation. Blood Cancer J. 2024;14:45.","journal-title":"Blood Cancer J"},{"key":"3033_CR19","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1038\/s41409-024-02284-5","volume":"59","author":"A Nagler","year":"2024","unstructured":"Nagler A, Labopin M, Swoboda R, Schroeder T, Hamladji R-M, Griskevicius L, et al. Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation from sibling and unrelated donors in patients with acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2024;59:1012\u201321.","journal-title":"Bone Marrow Transplant"},{"key":"3033_CR20","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13045-020-00923-0","volume":"13","author":"E Brissot","year":"2020","unstructured":"Brissot E, Labopin M, Moiseev I, Cornelissen JJ, Meijer E, Van Gorkom G, et al. Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10\/10 HLA-matched unrelated donors. J Hematol Oncol. 2020;13:87.","journal-title":"J Hematol Oncol"},{"key":"3033_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/cncr.33255","volume":"127","author":"G Battipaglia","year":"2021","unstructured":"Battipaglia G, Labopin M, Hamladji R-M, Blaise D, Chevallier P, Brissot E, et al. Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: a retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2021;127:209\u201318.","journal-title":"Cancer"},{"key":"3033_CR22","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"3033_CR23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1053\/bbmt.2003.50026","volume":"9","author":"SJ Lee","year":"2003","unstructured":"Lee SJ, Vogelsang G, Flowers MED. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9:215\u201333.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3033_CR24","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transpl. 2005;11:945\u201356.","journal-title":"Biol Blood Marrow Transpl"},{"key":"3033_CR25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1056\/NEJMoa2503189","volume":"393","author":"DJ Curtis","year":"2025","unstructured":"Curtis DJ, Patil SS, Reynolds J, Purtill D, Lewis C, Ritchie DS, et al. Graft-versus-host disease prophylaxis with cyclophosphamide and cyclosporin. N Engl J Med. 2025;393:243\u201354.","journal-title":"N Engl J Med"},{"key":"3033_CR26","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/s41409-020-0792-x","volume":"55","author":"F Bonifazi","year":"2020","unstructured":"Bonifazi F, Rubio M-T, Bacigalupo A, Boelens JJ, Finke J, Greinix H, et al. Rabbit ATG\/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel. Bone Marrow Transplant. 2020;55:1093\u2013102.","journal-title":"Bone Marrow Transplant"},{"key":"3033_CR27","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1182\/bloodadvances.2024014781","volume":"9","author":"N Desai","year":"2025","unstructured":"Desai N, Altareb M, Remberger M, Chen C, Alfaro Moya T, Al-Shaibani E, et al. PTCy-based graft-versus-host disease prophylaxis for matched sibling donor allogeneic hematopoietic cell transplantation. Blood Adv. 2025;9:660\u20139.","journal-title":"Blood Adv"},{"key":"3033_CR28","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1182\/blood.2019000487","volume":"134","author":"G Battipaglia","year":"2019","unstructured":"Battipaglia G, Labopin M, Kr\u00f6ger N, Vitek A, Afanasyev B, Hilgendorf I, et al. Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. Blood. 2019;134:892\u20139.","journal-title":"Blood"},{"key":"3033_CR29","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/s41409-026-02799-z","volume":"61","author":"N Desai","year":"2026","unstructured":"Desai N, Viswabandya A. PTCy versus ATG in HLA-matched sibling donor allogeneic transplantation: Comment on: Improved GVHD-free relapse-free survival when rATG\/ATLG is used in allo-HCT from matched sibling donors\u2013an EBMT registry study by the Transplant Complications Working Party. Bone Marrow Transplant. 2026;61:490\u20131.","journal-title":"Bone Marrow Transplant"},{"key":"3033_CR30","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41409-023-02131-z","volume":"59","author":"C Ustun","year":"2024","unstructured":"Ustun C, Chen M, Kim S, Auletta JJ, Batista MV, Battiwalla M, et al. Post-transplantation cyclophosphamide is associated with increased bacterial infections. Bone Marrow Transplant. 2024;59:76\u201384.","journal-title":"Bone Marrow Transplant"},{"key":"3033_CR31","first-page":"32.e1","volume":"31","author":"C Luo","year":"2025","unstructured":"Luo C, Huang X, Wu G, Huang Y, Ding Y, Huang Z, et al. Combination of anti-thymocyte globulin with post-transplant cyclophosphamide for gvhd prophylaxis in patients undergoing haploidentical hematopoietic stem cell transplantation: systematic review and meta-analysis. Transpl Cell Ther. 2025;31:32.e1\u201332.e15.","journal-title":"Transpl Cell Ther"},{"key":"3033_CR32","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1038\/s41409-022-01754-y","volume":"57","author":"Y Zu","year":"2022","unstructured":"Zu Y, Li Z, Gui R, Liu Y, Zhang Y, Yu F, et al. Low-dose post-transplant cyclophosphamide with low-dose antithymocyte globulin for prevention of graft-versus-host disease in first complete remission undergoing 10\/10 HLA-matched unrelated donor peripheral blood stem cell transplants: a multicentre, randomized controlled trial. Bone Marrow Transplant. 2022;57:1573\u201380.","journal-title":"Bone Marrow Transplant"},{"key":"3033_CR33","first-page":"536.e1","volume":"30","author":"MQ Salas","year":"2024","unstructured":"Salas MQ, Alfaro-Moya T, Atenafu EG, Datt Law A, Lam W, Pasic I, et al. Outcomes of antithymocyte globulin-post-transplantation cyclophosphamide-cyclosporine-based versus antithymocyte globulin-based prophylaxis for 10\/10 HLA-matched unrelated donor allogeneic hematopoietic cell transplantation. Transpl Cell Ther. 2024;30:536.e1\u2013536.e13.","journal-title":"Transpl Cell Ther"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03033-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03033-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03033-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T21:44:33Z","timestamp":1789249473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03033-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,12]]},"references-count":33,"alternative-id":["3033"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-03033-6","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,12]]},"assertion":[{"value":"8 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yves Chalandon: consulting fees for advisory board from MSD, Novartis, Incyte, BMS, Pfizer, AbbVie, Roche, Jazz, Gilead, Amgen, Astra-Zeneca, Servier, Takeda, Pierre Fabre, Medac, all via the institution; Travel support from MSD, Roche, Novartis, Pfizer, BMS, Gilead, Amgen, Incyte, AbbVie, Janssen, Astra-Zeneca, Jazz, Pierre Fabre, Sanofi all via the institution. Patrice Chevallier: Sanofi, MEDAC, Novartis, Immedica, Therakos. Florent Malard: Therakos, MSD, Priothera, AstraZeneca, Jazz Pharmaceutical, Sanofi. Ibrahim Yakoub-Agha: Novartis. Marie Robin: ABBVIE, ASTEX\/TAIHO; Edouard Forcade: Novartis, Sanofi, Alexion, Sobi, Jazz, Gilead. Tereza Coman: Pierre Fabre, MEDAC, Jazz, Sanofi, Neovi (travel support or consulting fees, all via the institution).","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The study was approved by the Ethics Evaluation Committee (CEE\/IRB00003888; approval No. 21-845, September 7, 2021; amendment approved May 6, 2025). All methods were performed in accordance with the relevant guidelines and regulations and with the Declaration of Helsinki. Informed consent was obtained from all participants for the collection and use of their clinical data for research purposes.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}